埃及慢性丙型肝炎相关肝细胞癌患者的血清微小RNA检测板

Serum miRNA Panel in Egyptian Patients with Chronic Hepatitis C Related Hepatocellular Carcinoma.

作者信息

Khairy Ahmed, Hamza Iman, Shaker Olfat, Yosry Ayman

机构信息

Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt E-mail :

出版信息

Asian Pac J Cancer Prev. 2016;17(5):2699-703.

PMID:27268654

Abstract

BACKGROUND

Primary hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. MicroRNAs (miRNAs) have great HCC diagnostic potential and circulating miRNAs have been reported as promising biomarkers for various pathologic conditions.

AIM

To explore the potential benefit of serum miR-126, miR-129, miR-155, miR-203 and miR-223 as non-invasive diagnostic markers of hepatitis C virus (HCV)-related HCC.

MATERIALS AND METHODS

The expression of miRNA was evaluated using real-time quantitative RT-PCR in 78 serum samples (30 treatment-naive chronic HCV, 25 post-HCV compensated cirrhosis and 23 treatment- naive HCC cases).

RESULTS

Comparing miRNA fold changes in the HCC group vs the non HCC groups, there was significant fold decrease in miR-126 (P= 0.034), miR-129 (P= 0.006), miR-155 (P= 0.011), miR-203 (<0.001) and miR-223 (P= 0.013). The highest AUC to differentiate HCC patients from non-HCC was 0.76 for miR-203.

CONCLUSIONS

Among studied miRNAs, serum miR-203 has the highest potential as a non-invasive biomarker of HCC.

摘要

背景

原发性肝细胞癌（HCC）是全球最常见的恶性肿瘤之一。微小RNA（miRNA）具有巨大的HCC诊断潜力，循环miRNA已被报道为各种病理状况的有前景的生物标志物。

目的

探讨血清miR-126、miR-129、miR-155、miR-203和miR-223作为丙型肝炎病毒（HCV）相关HCC的非侵入性诊断标志物的潜在益处。

材料与方法

使用实时定量逆转录聚合酶链反应（RT-PCR）评估78份血清样本（30例未经治疗的慢性HCV患者、25例HCV后代偿性肝硬化患者和23例未经治疗的HCC患者）中miRNA的表达。

结果

比较HCC组与非HCC组的miRNA倍数变化，miR-126（P = 0.034）、miR-129（P = 0.006）、miR-155（P = 0.011）、miR-203（<0.001）和miR-223（P = 0.013）有显著的倍数下降。miR-203区分HCC患者与非HCC患者的最高曲线下面积（AUC）为0.76。